Saniona AB: Saniona publishes prospectus for listing of shares on Nasdaq Stockholm

Print
| Source: Saniona AB
multilang-release

20170612 - PR - Prospectus - UK.pdf

PRESS RELEASE

12 June 2017

Saniona AB (publ) ("Saniona" or the "Company") has prepared a prospectus for admission to trading of the Company's shares at Nasdaq Stockholm. Last day of trading at Nasdaq First North Premier is June 14, 2017 and scheduled first day of trading at Nasdaq Stockholm is June 15, 2017.

The prospectus has today, June 12, 2017, been approved and registered by the Swedish FSA (Sw. Finansinspektionen) and is now available on the Company's website (www.saniona.com) and Pareto Securities' website (www.paretosec.se).

Pareto Securities AB has acted as financial adviser and Setterwalls Advokatbyrå AB as legal adviser in connection with the listing.

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com

The information was submitted for publication, through the agency of the contact person set out above, at 12:15 CET on 12 June 2017.

About Saniona

Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Proximagen Ltd., Productos Medix, S.A de S.V and Luc Therapeutics Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq First North Premier and has about 5,000 shareholders. Pareto Securities is Certified Advisor for Saniona. The company's share is traded under the ticker SANION. Read more at www.saniona.com.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/a77e0bee-8c37-445a-9129-9e1baae939ae